April 2022

Tech Giants Commit Nearly $1 Billion Toward Carbon Capture

Some of the world’s largest companies are teaming up to commit nearly $1 billion in spurring the carbon-capture market. On April 12, Stripe, Facebook, Alphabet, Shopify and McKinsey & Co. Inc. announced the creation of ... [Read]

EV Technology Group prepares for global growth with the appointment of former Lotus executive Dan Burge as Chief Product Officer and the opening of new United States office

Apr 25 EV Technology Group

TORONTO, April 25, 2022 – EV Technology Group Ltd., (NEO:EVTG) (the “Company”) announces today that it has strengthened its leadership team with the appointment of Dan Burge as Chief Product Officer, effective immediately. Dan Burge is ... [Read]

Global Antibiotic Resistance Market to Hit US$16.5 Billion By 2030

Apr 21 Stéphanie Bédard-Châteauneuf

Resistance to antibiotics is a growing concern. About 750,000 people die each year worldwide from drug–resistance infections. If solutions aren’t found and put in place, 10 million people could die from antibiotic resistance-related diseases by ... [Read]

Shenandoah Telecommunications Company Reports Q4 2021 and FY 2021 Results With Growth for Shentel

Apr 20 Matthew Evanoff

Shenandoah Telecommunications Company (NASDAQ:SHEN) announced its fourth quarter and full year financial and operating results on February 28, 2022. The telecom company, known as Shentel, provides broadband services. The company has high-speed, cable, fiber-optic, and ... [Read]

Why Psychedelics Could Soon Replace Antidepressants

Apr 13 Stéphanie Bédard-Châteauneuf

Anxiety disorders are the most common mental illness in the US, affecting approximately 40 million adults each year, and despite the abundance of antianxiety medications available, treatment resistance occurs in roughly 30% of patients. Anxiety ... [Read]

BridgeBio Pharma Announces Phase 2 Results From Acoramidis Study

Apr 11 Matthew Evanoff

BridgeBio Pharma (NASDQ:BBIO), a commercial-stage biopharmaceutical company developing medicines for patients suffering from genetic diseases and cancers with clear genetic drivers, recently reported updated results from its ongoing Phase 2 study for acoramidis. The study ... [Read]

Renren Inc. Announces Software License Agreement

Apr 8

PR Newswire PHOENIX , April 8, 2022 /PRNewswire/ — Renren Inc. (NYSE: RENN) (” Renren ” or the ” Company “), announces today that the Company, has signed a Software License and Distribution Agreement (” License ... [Read]